Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06433219
Status:
RECRUITING
Last Update Posted:
2024-05-29
First Post:
2024-05-22
Brief Title:
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer DDRiver EOC 302
Sponsor:
EMD Serono Research Development Institute Inc
Organization:
EMD Serono
Study Overview
Official Title:
An Open-label Multicenter Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant andor Homologous Recombination deficiency HRD-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy DDRiver EOC 302
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer The participants will previously have progressed while treated with a poly ADP ribose polymerase PARP inhibitor The primary objective of the study is to assess the effect of the treatment in terms of overall response ie whether the tumor disappears shrinks remains unchanged or gets worse
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2024-511202-23-00 | OTHER | EU trial number | None |